Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 5Hepatitis B, Chronic 3Hepatitis B 3Lymphoma 2Virus Diseases 1Recurrence 1Paraparesis, Tropical Spastic 1Neuritis 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Infections 1HTLV-I Infections 1Fibrosis 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Rituximab 10Valganciclovir 6Etoposide 4Doxorubicin 4Valacyclovir 3Gemcitabine 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3spartalizumab 2pembrolizumab 2pegaspargase 2Zidovudine 2Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Methylprednisolone 2Methotrexate 2Matrix-M 2Leucovorin 2Lenalidomide 2Cell Count 2Carboplatin 2Blood Specimen Collection 2Acyclovir 2valomaciclovir 1toripalimab 1threonic acid 1ruxolitinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epstein-Barr Virus Infections × Tenofovir × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡